ALOPECIA
In various AS101 experiments it was observed that the degree of Alopecia,
or hair loss, was much greater in the group treated with chemotherapy alone
than in the group treated with AS101 and chemotherapy.
Following these encouraging results, it was decided to test this further
on an animal model. Lewis rats were chosen for the experiment.
In the following experiment Alopecia, or the gradual loss of hair, was induced
by injecting the chemotherapeutic drug ARA-C, to seven groups of rats.
A constant dose of AS101 - 7.5 µg/rat - was used in the experiment
and was administered 2 hours before injecting the chemotherapeutic drugÆ
Each group included 4, 8-day-old rat.
Treatment lasted 7 days, and results were monitored on day 9.
In order to differentiate between the groups, rats were marked on their
backs.
One group served as control of uninjected rats.
The other groups were divided into two sets: one receiving 50 and the other
receiving 25 mg/kg of ARA-C.
The first set of rats included the following subgroups:
One subgroup was injected daily with the chemotherapeutic drug receiving
50 mg/kg of the ARA-C, alone.
In the second subgroup, AS101 was injected daily 2 hours before administering
the chemotherapeutic drug.
In the third subgroup, AS101 was injected every other day, 2 hours before
administering the chemotherapeutic drug.
The same protocol was followed with the second set of rats receiving 25
mg/kg of the ARA-C.
Alopecia is graded from (zero) 0-4.
In the control uninjected group no rats show alopecia.
In the first set receiving 50 mg/kg ARA-C, rats injected with the drug alone
developed grade 4 alopecia, whereas the majority of rats receiving AS101
every other day developed grade 3 alopecia, and those injected with ARA-C
+ AS101 every day developed grade 2 alopecia.
In the second set receiving 25 mg/kg of ARA-C, rats injected with the drug
alone, developed grade 4 alopecia, whereas rats injected with ARA-C + AS101
at both protocols, developed grade 1 alopecia.
It is clear that rats receiving AS101 every day developed the lowest grade
of alopecia.
In another experiment testing the ability of AS101 to prevent alopecia following
ARA-C treatment, AS101 was administered subcutaneously or applied directly
to the skin.
In this experiment there were 4 groups of rats:
The first group served as control of uninjected rats ;
The second group received 25 mg/kg of ARA-C only.
In the third group, every day, two hours before injecting rats with 25 mg/kg
of ARA-C , AS101 was injected subcutaneously to their backs at a concentration
of 2.5 mg/kg.
In the fourth group , rats received 25mg/kg of ARA-C, and AS101 was applied
directly to their skin at a concentration of 50mg/kg.
To clearly distinguish between the four groups, rats were marked on their
backs.
Treatment lasted for 7 days. Results were monitored on day 9.
In the control uninjected group, no rats show alopecia.
In the second group of rats receiving ARA-C only, rats develop grade 4 alopecia.
In the third group, fluffy hair can be seen on the back of the necks, whereas
the rest of the body shows grade 4 alopecia.
In the fourth group, grade 1 alopecia can be seen.
These results suggest that AS101 prevents alopecia induced by
ARA--C.
"NUDE" mouse before and after AS101 treatment
Chemotherapy treatment of Carboplatin + VP 16 with & without
AS101
